AbbVie (NYSE:ABBV) is a global, research-driven biopharmaceutical company headquartered in North Chicago, Illinois. Established in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on discovering, developing and marketing advanced therapies that address some of the world’s most complex and critical health challenges. Its business model emphasizes investment in innovation, strategic partnerships and targeted acquisitions to broaden its therapeutic portfolio.
The company’s product lineup spans immunology, oncology, neuroscience, virology and eye care. AbbVie’s leading products include therapies for autoimmune conditions—such as rheumatoid arthritis and psoriasis—as well as treatments for chronic lymphocytic leukemia, hepatitis C and other serious illnesses. AbbVie also maintains a robust research and development pipeline, investigating novel biologics, small molecules and combination therapies designed to improve patient outcomes across multiple disease areas.
With operations in more than 75 countries and product registrations in over 170 markets, AbbVie maintains a global commercial footprint supported by manufacturing facilities in North America, Europe and Asia. The company collaborates with academic centers, biotechnology firms and healthcare organizations worldwide to accelerate clinical development and to ensure broad patient access to its medicines.
AbbVie is led by Chairman and Chief Executive Officer Richard A. Gonzalez, under whose tenure the company has expanded its therapeutic reach and strengthened its innovation capabilities. Since its inception, AbbVie has pursued a transparent governance framework and long-term strategic planning, positioning itself as a prominent player in the global pharmaceutical industry.
